Nektar sells off royalties on its 2 approved drugs for $150M in cash, redoubling focus on I-O candidates

A little less than a year ago, an FDA adcomm unanimously rejected Nektar Therapeutics’ opioid program, effectively sending it to the chopping block. Now, looking for a quick cash infusion to finance clinical tests for two other candidates, Nektar will sell off royalties for its only two approved US medicines.